Enter multiple symbols separated by commas

Stocks Roche Holding AG


  • Avalanche drops eye drug trial, takes it back to lab Thursday, 13 Aug 2015 | 5:50 PM ET

    Aug 13- Drug developer Avalanche Biotechnologies Inc said it would not start a second mid-stage study of its eye drug, which showed only a modest improvement in vision in the first study. While the 11.5- letter difference that AVA-101 showed in the first mid-stage study was significant, patients treated with Roche Holding AG's Lucentis and Regeneron Inc's...

  • Aug 12- AbbVie Inc on Wednesday said its experimental treatment for a form of leukemia associated with a gene mutation met its primary goal in a mid-stage trial and that the company would seek U.S. approval of the medicine, which analysts have said has blockbuster sales potential. AbbVie, which is developing the drug venetoclax with Switzerland's Roche Holding...

  • July 24- The U.S. Food and Drug Administration approved Novartis AG's oral pill to treat the most common form of advanced skin cancer. Roche Holding AG's Erivedge was the first pill to be approved in 2012 by the FDA for the condition. One in five Americans are likely to develop skin cancer in their lifetime, according to the American Academy of Dermatology.

  • NEW YORK, June 30- The United States says Novartis AG should pay as much as $3.35 billion in damages and civil fines because the Swiss drugmaker used kickbacks to boost sales of two drugs covered by Medicare and Medicaid. In papers filed Monday night in Manhattan federal court, the government said it deserves that sum under the federal False Claims Act over...

  • The U.S. Court of Appeals for the Federal Circuit in the District of Columbia said a patent held by genetic testing company Sequenom Inc on detecting fetal DNA in a pregnant woman's blood was invalid. Sequenom's innovation was in finding a way to use DNA found in maternal blood samples that had previously been discarded as medical waste in order to determine...

  • CHICAGO, June 2- Drugmakers including Bristol-Myers Squibb Co and Merck& Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a biomarker, may be too unreliable, researchers and health experts said. Competitors Roche Holding, AstraZeneca and Pfizer also have similar drugs in...

  • Europe shares close mixed; Greece in focus Monday, 1 Jun 2015 | 12:08 PM ET

    European equities closed mixed on Monday as investors reacted to new economic data and cheered updates from the pharmaceutical sector.

  • After BMY's drop, cancer drug stocks set to move? Monday, 1 Jun 2015 | 5:00 AM ET
    Attendees walk through the lobby at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. (File Photo).

    The stock-moving news flow started early out of the American Society of Clinical Oncology meeting in Chicago.

  • Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival in a trial of patients with the most common form of lung cancer, but it did not work in patients who tested negative for a specific protein in their tumors, leading to a nearly 7 percent sell-off in the company's shares on Friday. The Bristol drug was approved by U.S. regulators in December to...

  • Here's why Puma, Clovis shares are poised to move Friday, 29 May 2015 | 2:49 PM ET
    Attendees walk through the lobby at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. (File Photo).

    It's that time again. With researchers set to convene at the American Society of Clinical Oncology meeting, here are the stocks to watch.

  • Linking cancer drug prices to their performance Wednesday, 27 May 2015 | 1:54 PM ET

    Express Scripts is looking at the possibility of paying more for drugs that have been proven to show more benefit, and less where the drug hasn't.

  • --Amgen in late 2012 bought Decode Genetics for $415 million in cash to gain access to a database of complete genetic sequences of 2,636 Icelanders. --In January 2014, Regeneron Pharmaceuticals Inc signed a deal with Geisinger Health System in Pennsylvania to sequence DNA from as many as 250,000 volunteers from Geisinger's pool of 3 million patients.

  • Regeneron Pharmaceuticals Inc, which signed a deal with Pennsylvania's Geisinger Health System in January 2014 to sequence partial genomes of some 250,000 volunteers, is already claiming discoveries based on the new approach. Pfizer Inc, Roche Holding AG and Biogen Inc are working on similar projects that use DNA and patient health data to find new drug...

  • May 7- Regeneron Pharmaceuticals Inc said it expects sales of blockbuster eye drug Eylea to grow even more quickly following data that showed it was superior to rival treatments. Sales of Eylea in the United States leapt 51 percent to $541 million in the first quarter ended March 31, helping the company's adjusted profit handsomely beat the average analyst...

  • NEW YORK, May 6- Drugmakers are building safety "switches" that can be used to turn off powerful cancer therapies known as CAR T cells when they cause life-threatening inflammation or attack healthy tissue. *Bellicum Pharmaceuticals Inc has developed a "switch" by genetically programming a CAR T cell to kill itself when exposed to a drug called rimiducid,...

  • IBM's Watson to guide cancer therapies at 14 centers Tuesday, 5 May 2015 | 2:00 PM ET

    NEW YORK, May 5- Fourteen U.S. and Canadian cancer institutes will use International Business Machines Corp's Watson computer system to choose therapies based on a tumor's genetic fingerprints, the company said on Tuesday, the latest step toward bringing personalized cancer treatments to more patients. Faced with such a data deluge, "the solution is going to be...

  • Novartis warns of currency drag on 2015 earnings Thursday, 23 Apr 2015 | 2:07 AM ET

    Swiss drugmaker Novartis posted declining sales in the first quarter and cautioned that dollar strength may be a bigger-than-expected drag.

  • Europe ends mixed as investors digest earnings Wednesday, 22 Apr 2015 | 12:23 PM ET

    European shares finished mixed on Wednesday, as investors digested a slew of earnings from European companies.

  • Roche CEO downplays hit from Swiss franc on results Wednesday, 22 Apr 2015 | 3:16 AM ET

    Roche, the world's biggest maker of cancer drugs, reported a 3 percent rise in sales in the first quarter on Wednesday.

  • Biotech investors brace for updates on key drugs Friday, 17 Apr 2015 | 1:44 PM ET
    Lab technician handling test tubes

    Biotech investors are going to be busy with new data on Alzheimer's drugs, cancer and genetic disorders on the way. Here's what analysts are watching.